Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection

Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
The case fatality rate in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emergent cause of the COVID-19 pandemic, rises from 2.3 to 10.5% in individuals with cardiovascular comorbidities. Transmission electron microscopy has been used to confirm the presence of SARS-CoV-2 viral particles in human cardiomyocytes infected in vitro with the virus, or in autopsy samples from patients positive for SARS-CoV-2. Further, SARS-CoV-2 infection in induced pluripotent stem cell (iPSC)-derived cardiomyocytes induces morphological and cytotoxic effects, and sarcocere disruption in autopsy samples is observed, suggesting SARS-CoV-2 directly damages cardiac tissue.

Entry of SARS-CoV-2 into host cells is dependent on the high-affinity binding of primed viral spike (S) protein to cell surface angiotensin-converting enzyme 2 (ACE2). Priming of S protein, through proteolytic cleavage of S1/S2 and S2’ sites is mediated by transmembrane protease, serine 2 (TMPRSS2), also present at the cell surface. Further host protein components are implicated in SARS-CoV-2 infection, including the endosomal proteases furin and cathepsins, involved in S1/S2 cleavage and endosomal processing, respectively. B0AT1 (SLC6A19) is a neutral amino acid transporter whose surface expression is critically regulated by ACE2. Interestingly, an ACE2-B0AT1 heterodimer complex was shown using cryogenic electron microscopy to be able to bind two SARS-CoV-2 S proteins simultaneously. Additionally, the B0AT1 component of ACE2-B0AT1 heterodimer complexes was evidenced as a major player in ACE2 engagement with TMPRSS2 by molecular docking modelling. A number of comprehensive reviews outlining potential drug targets for SARS-CoV-2 therapy have been published.

We previously demonstrated expression of genes for the proteins listed above in human cardiomyocytes, and have shown they are significantly upregulated in aged patients, providing a rationale for increased susceptibility to SARS-CoV-2 infection in the elderly population. Our aim was to determine whether a human embryonic stem cell-derived cardiomyocyte (hESC-CM) model expresses the same repertoire of recognition, processing, and ancillary genes (and corresponding proteins) as observed in adult cardiomyocytes, and demonstrate viral entry of SARS-CoV-2 in this model. Human stem cell lines used to generate cardiomyocytes are widely acknowledged for their usefulness in cardiovascular medical research and will be critical in understanding the recognised pathology of SARS-CoV-2 in this tissue type, alongside providing a suitable model for drug screening. The previous reports have shown that human iPSC-derived cardiomyocytes are susceptible to infection by SARS-CoV-2 in an ACE2-dependent manner, with a role for cathepsins, and authors conclude that these cells would be tractable to a high throughput screen. As a secondary aim, therefore, we looked to validate infection of hESC-CMs using a quantitative automated system in conjunction with a pseudotyped HIV-1 based lentivirus decorated with the SARS-CoV-2 spike protein, and screen for novel therapeutic agents that inhibit infection. Previous authors have outlined the potential of such a system using a pseudotyped virus but it has yet to be put into practice to discover effective compounds in clinically relevant derived cardiomyocytes.

Results and discussion

Human embryonic stem cell-derived cardiomyocyte express the protein machinery exploited by SARS-CoV-2. We confirm the presence of host cell proteins associated with SARS-CoV-2 infection using immunocytochemistry in the hESC-CM line, and using immunohistochemistry in human left ventricle tissue sections (Fig. 1a–g). This is critical as the expression of receptor recognition and viral entry proteins may vary with cell type. Quantification demonstrated positive immunolabelling above background and control hESC-CMs, with >90% of the population showing immunolabelling for ACE2, TMPRSS2, cathepsin L, and furin (Fig. 1h). B0AT1 immunoreactive signal was observed in 55.6 ± 9.1% of the cell population, while no significant cathepsin B immunoreactive signal (6.3 ± 2.3%) was observed above background (4.1 ± 1.6% of cells) (Fig. 1h). Results were recapitulated in human left ventricle sections, with immunolabelling detected for all proteins, except cathepsin B, which again displayed little to no immunoreactivity. Expression of the corresponding genes for the proteins listed above was also demonstrated in hESC-CMs and human left ventricle tissue, except CTSB in the ventricular tissue (Fig. 1i). Interestingly, others have also found CTSB mRNA in a human iPSC-derived cardiomyocyte model but the lack of cathepsin B protein identified, at least by immunocytochemistry in the hESC-CM line in our study, may point to discrepancies in the mRNA expression versus actual protein.

After demonstrating the presence of the protein complement required for SARS-CoV-2 viral entry in hESC-CMs, we infected these cells with SARS-CoV-2 and successfully showed titre- and time-dependent levels of infection (Supplementary Fig. 1).

In wells treated with drugs targeting the proteins involved in SARS-CoV-2 viral entry and processing, we observed significant reductions in levels of infection. See Supplementary Table 1 for a summary of the compounds used. An ACE2 antibody, that has been shown previously to neutralize pseudotyped virus and SARS-CoV-2 infection, was effective in our drug screen, significantly reducing infection level to 2.9 ± 0.4%, as was DX600, the ACE2 peptide antagonist, which reduced infection to 20.5 ± 6.5% in the observed cells. Note that the ~7 fold lower reduction in infection by DX600 versus the antibody may be due to the comparative concentrations used, or the different mechanisms of action that the two exhibit. DX600 is a highly selective peptide that has not been tested previously as a viral entry inhibitor but forms multiple interactions with the catalytic site, that is distinct from the receptor-binding domain of the virus. However, binding of DX600 may be sufficient to change the conformation of ACE2, or induce steric hindrance, to inhibit spike binding from within the catalytic site, whilst the antibody is considerably larger and binds to multiple epitopes of ACE2.

The ACE2 antibody did not significantly reduce the rate of infection with control vesicular stomatitis virus (VSV-G) pseudotyped lentivirus (Fig. 2b–d) (65.2 ± 6.7% in the absence of the antibody and 58.3 ± 6.7% in its presence), providing evidence for ACE2 dependency of the SARS-CoV-2 spike-pseudotyped lentiviral entry. Uninfected cells were treated with media that did not contain pseudotyped lentivirus particles and showed little to no infection. These results confirm the requirement of expression of ACE2 in these cells for receptor recognition and viral entry, with no evidence for direct membrane fusion, as is common with other viruses.
Camostat and E64d, inhibitors of the accessory proteins TMPRSS2 and cathepsins, respectively, significantly reduced infection levels to 20.5 ± 6.5% and 7.8 ± 1.7%. A mix of camostat and E64d effectively reduced infection rate as well (6.5 ± 1.5%) but this was not significantly different from E64d treatment alone. These results suggest that inhibition of viral entry can be achieved at distinct steps of viral entry and processing. Importantly, camostat is already clinically approved in Japan where it is used to treat chronic pancreatitis, and is considered well-tolerated and safe. Additionally, camostat has been previously confirmed as an effective inhibitor of pseudotyped virus and SARS-CoV-2 infection. Interestingly, benztropine, a small molecule inhibitor of the potential ancillary protein for viral entry, B0AT1, also successfully reduced pseudotyped virus infection levels (28.9 ± 8.8%). The compound is used clinically as an adjunct in the therapy of all forms of parkinsonism but the precise mechanisms behind its inhibition of viral infection require further investigation. It is important to note that B0AT1 is found associated with ACE2 in high abundance in the gastrointestinal tract.

The cell counts in the observed regions in the Opera Phenix (Fig. 2e), confirmed that hESC-CM number was not significantly altered in the presence of the compounds tested versus the media or DMSO (0.6%) treated cells, confirming that treatments were unlikely to be toxic. Uninfected cells and those cells treated with pseudotyped lentivirus were also all present in comparable numbers, suggesting the viral inoculation was not inherently toxic. Cardiomyocytes were confirmed as beating visually, at a similar frequency in populations treated with either SARS-CoV-2 spike, VSV-G (control) pseudotyped lentivirus or media control, and a troponin-T cardiac-specific marker demonstrated that hESC-CM populations were >95% pure (Supplementary Fig. 2 and Supplementary videos #1–5).

**Conclusions**

Our results have identified and validated a qualitative and quantitative screen, crucially using hESC-derived beating cardiomyocytes, where these clinically relevant cells are not rate limiting and widely available. We have demonstrated these are also viable and can be handled reliably in 96 well plates, the minimum format usually required for high throughput screens. hESC-CMs are shown here to allow for the identification of current clinically approved medicines and the discovery of novel compounds directed against the host protein targets used by SARS-CoV-2 to infect cells. The pseudotyped lentiviral system can also be handled at intermediate Biosafety levels, or containment levels of two meaning independent research groups will be able to use this system.
**Fig. 2 SARS-CoV-2 spike-pseudotyped viral infection, and pharmacological inhibition, in hESC-CMs.**

**a** Schematic showing the experimental workflow in brief for generating human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and taking them into the pseudotyped lentiviral infection drug screen before conducting quantitative imaging (see Methods for further details). The schematic was generated using templates from Servier Medical Art (https://smart.servier.com/).

**b** Representative fluorescent confocal images ($n=2$ independent experiments performed in triplicate) of hESC-CMs pretreated with small molecule inhibitors (camostat, benztropine, and E64d), peptide antagonist (DX600), or antibody (ACE2 Ab) targeting protein components involved in SARS-CoV-2 infection. Control cells were treated with DMSO (0.6%) or media. Cells were treated with drugs for 1 h before incubation with SARS-CoV-2 spike-pseudotyped GFP-expressing (green) lentivirus for 4 h. After removal of viral particles, cells were washed and maintained in the presence of drugs for 5 days before fixation with 4% formaldehyde and staining with Hoechst 33342 nuclear marker (blue). Scale bar shows 200 μm.

**c** Representative fluorescent confocal images ($n=2$ independent experiments performed in triplicate) of control human embryonic stem cell-derived cardiomyocytes (hESC-CMs) treated with VSV-G pseudotyped GFP-expressing (green) lentivirus, in the absence (upper) or presence (middle) of antibody (ACE2 Ab). Uninfected controls were not treated with viral particles (bottom). Again, cells were stained with Hoechst 33342 nuclear marker.

**d** Graphical data showing the percentage of observed hESC-CMs infected with either SARS-CoV-2 spike or VSV-G (control) pseudotyped lentivirus in the presence of drugs or DMSO (0.6%) as indicated. Uninfected controls were not treated with viral particles (bottom). Agin, cells were stained with Hoechst 33342 nuclear marker. **p < 0.005; ***p < 0.0005; ****p < 0.00005; and ns = no significant difference (as determined by one-way ANOVA) for each condition versus the DMSO treated control cells. # = no significant difference for condition versus the VSV-G control.

**e** Graphical data showing the overall count of observed hESC-CMs for each condition, as indicated. No condition showed a count significantly different (as determined by one-way ANOVA) from the DMSO treated control cells. All graphical data are mean ± SEM, with individual data points indicated.
target. DX600, as a specific and potent peptide inhibitor of ACE2, was hypothesised as a potential antiviral for SARS-CoV-2 and related viruses, and our study is the first to our knowledge to confirm this.

New medicines will be required for prophylactic treatment for those where vaccination against SARS-CoV-2 is contraindicated, and for the need to protect the heart against acute damage during hospitalization, as well as during prolonged postviral recovery observed in certain individuals. Furthermore, vaccine pressure is likely to result in resistant strains and a screening campaign is needed to add inhibitors of viral entry to our armamentarium, a strategy that has proved remarkably successful in other instances, such as maraviroc treatment in HIV cases. Our results provide a platform that has passed proof-of-principle to generate high-quality data in preclinical studies to justify translational research in animal models of acute respiratory distress syndrome and the repurposing of current drugs for clinical trials.

Methods

hESC culture and differentiation to cardiomyocytes. Pluripotent H9 hESCs (WiCell) were maintained in culture as described previously (Cheung et al.27). hESCs were grown as colonies in Essential 8 medium (E8), supplemented with fibroblast growth factor 2 (FGF,22.5 ng/ml, Qkine Ltd), and TGF-β (1.74 ng/ml, R&D Biotechnic), on culture plates previously coated with vitronectin (Stem cell technologies). A previously optimised protocol was used to induce differentiation of hESCs for spontaneous contracting cardiomyocytes (adapted from Mendjan et al.28). Briefly, differentiation was directed towards mesoderm lineage by culturing in CDM-BSA media supplemented with FGF2 (20 ng/ml), Activin-A (50 ng/ml), and Bone Morphogenetic Protein 4 (BMP4, 10 ng/ml, Bio-Techne) plus Sodium-Lactate (SIGMA). At the end of the selection, purity was assessed using the opera Phenix high-content screening system methods for immunocytochemistry. hESC-derived cardiomyocytes in CellCarrier-96 Ultra Plates (PerkinElmer) were washed 3x with 100 µL PBS before fixation with 4% paraformaldehyde for 20 mins. Subsequently, non-specific staining was blocked with PBS containing 5% donkey sera for 2 h at room temperature (RT). To remove non-specific signals, cells were air-dried and stained with rabbit polyclonal antibody to furin (ab3467; Abcam; 1:500), all prepared in PBS containing 0.3% Triton X-100. After washing with PBS containing 0.1% Tween-20 before incubation with the secondary polyclonal Donkey Anti-Goat IgG H&L antibody conjugated to Alexa Fluor 488 (Molecular Probes). Finally, cells were visualised with AF488 fluorescence using the opera Phenix High-Content Screening System.

Flow cytometry. hESC-derived cardiomyocytes were collected as pellets and resuspended in Fixation/Solubilization solution (BD Cytofix/Cytoperm Fixation/Permeabilization Kit, Biosciences) for 30 mins at 4 °C. Cells were then pelleted by centrifugation, washed three times in phosphate-buffered saline containing 0.1% BSA and 2 mM EDTA (PBE), and then resuspended in PBE containing FITC-conjugated antibody specific for cardiac troponin T (Milenyi Biotec, cat no. 130-119-575) at a concentration of 1:50 and incubated for 2 h at 4 °C. Three washes were performed using PBE and then cells were resuspended in PBE and run on LSz/Versetta X-20 Flow Cytometer (BD Biosciences). Analysis was performed using FlowJo software (BD Biosciences). This research was supported by the Cambridge NIHR BRC Cell Phenotyping Hub.

SARS-CoV-2 virus stock. The SARS-CoV-2 virus used in this study is the clinical isolate named "SARS-CoV2/human/Liverpool/REMQR00801/2020". In total, the stock used was passaged three times in Vero E6 cells, once in Calu3 cells, and once in Calu3 tissues. The titre of the virus stock was determined by TCID50 (Median Tissue Culture Infectious Dose) assay on HuH7 cells transduced with an ACE2 expression vector.

SARS-CoV-2 immunostaining. SARS-CoV-2-infected cells were fixed in 2% formaldehyde for 30 mins and permeabilised with 0.1% Triton X-100 in PBS. Cells were then blocked with 1% GlutMAX, 100 units/ml penicillin, and 100 µg/ml streptomycin (all from Thermo Fisher), at 37 °C in 5% CO2. Cells were confirmed mycoplasma negative (MycoAlert, Lonza).

Plasmids. Plasmid pCG1-SARS-CoV-2 Δ19 D614G HA, encoding the SARS-CoV-2 spike protein carrying a Δ19 change, with the C-terminal 19 amino acids replaced with an HA Tag, was generated from pCG1-SARS-2-S (a kind gift from M. Hoffmann29 by PCR (Phusion polymerase (NEB)) using primer pairs: (1) CoV2z01For (TTGTATCGGATCACCAGTGTGTTGTTCGCTTGTGCTCTG) with CoV2z01(11)R (CAGGTGAGGATTGGATTCTATCAGACGCAGC) and (2) CoV2z01(11)R with CoV2z01(11)F (GTGAAGGATTGGATTCTATCAGACGCAGCAGC). The generated plasmid was transfected into 293T cells using TransIT-293 transfection reagent (Mirus) according to the manufacturer’s recommendations. For infection of HEK293T cells with pHSIN CGW eGFP, viral supernatants were generated following co-transfection of HEK293T cells with pHSIN CGW eGFP and packaging plasmid pCMV8R89 and the core IDM (VSV-G) or pCG1-SARS-CoV-2 Δ19 D614G HA spike plasmid, using TransIT-293 transfection reagent (Mirus) according to the manufacturer’s recommendations. Viral supernatants were harvested 48 h post-transfection and cell debris was removed with a 0.45-µm syringe filter, before concentration (approximately 10-fold) using a Vivacell 20 MWCO 100 kDa centrifugal concentrator (Sartorius) according to manufacturer’s recommendations.

Pseudotyped lentivirus production. Pseudotyped lentivirus supernatants were generated following co-transfection of HEK293T cells with pHSIN CGW eGFP, plus the packaging plasmid pCMV8R89 and both pMD.G (VSV-G) or pCG1-SARS-CoV-2 Δ19 D614G HA spike plasmid, using TransIT-293 transfection reagent (Mirus) according to the manufacturer’s recommendations.

Concentrated pseudotyped lentivirus production. concentrated lentivirus supernatants were generated following co-transfection of HEK293T cells with pHSIN CGW eGFP, plus the packaging plasmid pCMV8R89 and both pMD.G (VSV-G) or pCG1-SARS-CoV-2 Δ19 D614G HA spike plasmid, using TransIT-293 transfection reagent (Mirus) according to the manufacturer’s recommendations.
conjugated to Alexa Fluor 555 (ab150066; Abcam; 1:200) prepared at 0.01 mg/ml in PBS for 15 mins at room temperature in the dark.

For viral infection experiments, pseudotyped virus-treated hESC-derived cardiomyocytes in CellCarrier-96 Ultra Plates (PerkinElmer) were washed 3x with 100 μL PBS before complete submersion in 2-4% formaldehyde solution for 30 mins. After fixation, hESC-derived cardiomyocytes plated in CellCarrier-96 Ultra Plates (PerkinElmer) were washed 3x with 100 μL PBS before incubation with Hoechst 33342 (H3570; Invitrogen) prepared at 10 μg/ml in PBS for 15 mins at room temperature in the dark. Cells were washed a further 3x with 100 μL PBS and maintained in 100 μL PBS for imaging.

Fluorescent confocal images of cells were acquired using the Opera Phenix High-Content Screening System (PerkinElmer) microscope with a 40x/NA1.2 water immersion objective. The Opera Phenix is a dual camera, sequential, multiple laser, spinning disk confocal microscope that acquires images in a fast and gentle manner to minimise fluorescent bleaching. For immunocytochemistry, excitation/emission laser and filter sets for two fluorescent channels were used: 405/435–480 nm (blue) for the Hoechst 33342 nuclear stain, and 488/500–550 nm (yellow) for the Donkey Anti-Goat IgG H&L antibody conjugated to Alexa Fluor 555 (ab150066; Abcam) or Donkey Anti-Rabbit IgG H&L antibody conjugated to Alexa Fluor 555 (ab150130; Abcam) or Donkey Anti-Rabbit IgG H&L antibody conjugated to Alexa Fluor 555 (ab150066; Abcam). For viral infection experiments, excitation/emission laser and filter sets for two fluorescent channels were used: 405/435–480 nm (blue) for the Hoechst 33342 nuclear stain, and 488/500–550 nm (green) for GFP or the donkey antieosin antibody conjugated to Alexa Fluor 488 (Jackson ImmunoResearch; catalog #111-222-014). Laser intensity was set at 100% for blue or 405 (445 nm and 488 nm) channels, respectively, and both were set to 50% transmission, with a 50 μs exposure time. Opera Phenix hardware focus ensures a consistent focal depth across the CellCarrier-96 Ultra Plate is achieved. Scale bars show 50 μm unless specified otherwise.

In-built Opera Phenix quantitation was performed using Harmony High-Content Imaging and Analysis Software (PerkinElmer). For analysis, images were filtered, and the contrast of the Hoechst nuclear blue channel was increased fivefold to ensure cells were distinguished from the background and to assist in finding the outline of individual cells. Fluorescence intensities were then calculated for every observed cell in the selected population and were deemed positive where whole-cell fluorescent (averaged over individual cell area) was ≥130 fluorescent units, where the background was determined as ~113 fluorescent units.

RNA extraction for RNA-seq. Total RNA extraction was performed using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. Briefly, for iPS-derived cardiomyocytes, cell pellets were thawed and 1 ml TRIzol reagent and incubated for 5 mins to allow nucleoprotein dissociation. For the human heart, tissue was homogenized mechanically in 1 ml TRIzol reagent using a Polytron and incubated for 5 mins to allow nucleoprotein dissociation. In each sample, 180 μl of chloroform was added, mixed thoroughly, and incubated for 3 mins at room temperature. Samples were then centrifuged at 12,000 x g for 15 mins at 4 °C to promote phase separation. The RNA-containing upper aqueous phase was transferred to a fresh sterile 1.5 ml microcentrifuge tube. Isopropanol (500 μl) was added and incubated for 10 mins to precipitate RNA. Samples were then centrifuged at 10,000 x g for 10 mins at 4 °C, the supernatant discarded, and RNA precipitate collected as a pellet. The pellets were resuspended in 1 ml 75% ethanol, vortexed briefly, and spun at 7,500 x g for 5 mins to wash the RNA pellet. The supernatant was discarded, and pellets were allowed to air dry for 10 mins at room temperature before being dissolved in 20 μl RNase-free water. RNA concentration was determined using a NanoDrop 1000 (Thermo Fisher), and RNA samples were subsequently stored at −70 °C before RNA sequencing library preparation.

RNA processing and sequencing

Quality control. RNA quality was verified using the TapeStation RNA ScreenTape (Agilent). All control HLV1 and stem cell RNA samples had RIN ≥ 7.14 (7.50 ± 0.23). qC. was performed using Agilent’s Small RNA LabChip kit (Agilent Technologies, Inc.) according to the manufacturer’s protocols. Ribosomal RNA was removed using NEBNext® rRNA Depletion Kit (Human/Mouse/Rat) (New England Biolabs) according to the manufacturer’s instructions with 6 μl total RNA used as input per sample. Total stranded RNA-seq sequencing library preparation and quality control: total stranded RNA-sequencing libraries were generated using the CORALL Total RNA-Seq Library Prep Kit (Lexogen) according to manufacturer’s instructions, with 15 PCR cycles used for the final amplification step and passed through quality control using a 2100 Bioanalyzer (Agilent). Both quality control and sequencing were carried out at the Babraham Institute Next Generation Sequencing Facility. 15 RNA-seq libraries were sequenced per lane of an Hiseq2500 (Illumina) as 100 bp Single-End sequencing runs.

Data analysis

Analysis and processing of next-generation sequencing data. All next-generation sequencing data were aligned using HISAT2 (http://daehwankimlab.github.io/hisat2/) to the Homo sapiens reference genome GRCh38/hg38. Reads were trimmed before alignment using Trim Galore, using Phred quality score for base calling cut-off of 20, corresponding to a maximum error of 1 in 100 bases and with a maximum trimming error rate of 0.1 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed and aligned sequence files were imported as BAM files into SeqMonk (v1.42.0) for visualization and analysis (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/).

RNA-seq analysis for differential gene expression. Sequencing reads were quantified by read count quantitation and global normalisation was performed to total read count for each replicate and expressed as reads per million (RPKM). A screen of a number of different cell types from different species found inconsistency between samples using RPKM and that using RPKM for normalisation did not respect the invariance property. Differential gene expression analysis was performed using the R-based software DESeq2 (35). Raw (non-log transformed) read counts were used as input and global normalization was performed to total library size. RPKM values ≥1.0 were deemed to be above the noise. Benjamini-Hochberg correction for multiple testing was used with a false discovery rate of 5%.

RNA-seq reproducibility and quantitative data. All quantitative data are expressed as mean ± SEM. The n values are biological replicates of different differentiations of hESC to cardiomyocytes and are stated in the methods and/or the figure legends. Statistical one-way ANOVA tests with Dunnett’s correction for multiple comparisons were used. A p value of <0.05 was determined as significant. Graphical presentation and

**ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02453-y**
statistical analyses were performed using GraphPad Prism version 6.07 for Windows (GraphPad Software, La Jolla, California, USA).

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**
The source data for graphs and charts are available as Supplementary data 1 and any remaining information can be obtained from the corresponding author upon reasonable request. RNA data are available from European Nucleotide Archive, accession number PRJEB43469, study name ena-STUDY-MAASTRICTHER-UNIVERSITY-08-03-2021:01:44:31:567-1586.

Received: 17 February 2021; Accepted: 15 July 2021; Published online: 29 July 2021

**References**
1. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. China, CDC weekly vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)—China, 2020. CCDC. 2, 113–122 (2020).
2. Watkins, J. Preventing a covid-19 pandemic. BMJ. 368, m810 (2020).
3. Sommerstein, R. Preventing a covid-19 pandemic. BMJ. 368, m810 (2020).
4. Pérez-Bermejo, J. A. et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Sci. Transl. Med. 13, eaeh7872 (2021).
5. Bojkova, D. et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc. Res. 116, 2207–2215 (2020).
6. Bullamante, G. P. et al. Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement. Biomedicines. 8, 626 (2020).
7. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367, 1260–1263 (2020).
8. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 581, 221–224 (2020).
9. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181, 271–280 (2020).
10. Cheng, Y. et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 33, 108254 (2020).
11. Liu, P. P. et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 142, 68–78 (2020).
12. Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 367, 1444–1448 (2020).
13. Stevens, B. R. TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney. bioRxiv https://doi.org/10.1101/2020.10.31.363473 (2020).
14. Alexander, S. P. H. et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. BIP 177, 4942–4966 (2020).
15. Xiu, S. et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J. Med. Chem. 63, 12256–12274 (2020).
16. Robinson, E. L. et al. Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes. J. Mol. Cell. Cardiol. 147, 88–91 (2020).
17. Yi, J. H. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4892 (2014).
18. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4892 (2014).
19. Cheng, Y. et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 278, 15533–15540 (2003).
20. Cheung, C. et al. Directed differentiation of embryonic origin-specific vascular smooth muscle subtypes from human pluripotent stem cells. Nat. Protoc. 9, 929–938 (2014).
21. Bojkova, D. et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc. Res. 116, 2207–2215 (2020).
22. Wu, F. et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 33, 108254 (2020).
23. Ikeda, Y. et al. Continuous high-titer HIV-1 production. Nat. Biotechnol. 21, 569–572 (2003).
24. Wagner, G. P., Kin, K. & Lynch, V. J. Measurement of mRNA abundance using RNA-seq data: RPMK measure is inconsistent among samples. Theory Biol. 131, 281–285 (2012).
25. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DSEq2. Genome Biol. 15, 550 (2014).

**Acknowledgements**
E.J.D.G. SARS-CoV2/human/Liverpool/RERMO001/2020 was a kind gift from Lance Turtle (University of Liverpool) and David Matthews and Andrew Davidson (University of Bristol). This research was funded in whole, or in part by: Wellcome Trust (WT107715/Z/15/Z, A.P.D., J.J.M.); Addenbrooke’s Charitable Trust (P.J.L., A.P.D.); Wellcome Trust Programme in Metabolic and Cardiovascular Disease (203814/Z/16/A, T.L.W., D.N.); Wellcome Trust Major Award (208363/Z/17/Z) for Imaging Core (G.S.); Wellcome Trust Principal Research Fellowship (210688/Z/18/Z, P.J.L.); UKRI/NHR through the UK Coronavirus Immunology Consortium (P.J.L.); Rosetrees Trust Charity (G103718, J.R.Z.); British Heart Foundation (FS/17/61/33473 APD, S.S., R.G.C.M, TAF provided laboratory support; P.J.L. and S.S. supervised experiments and contributed grant support and facilities; J.J.M. and A.P.D. designed and supervised experiments, performed data analysis, contributed grant support, and facilities. All authors contributed to the writing and/or review of the manuscript.

**Author contributions**
T.I.W. and M.T.C. designed and carried out experiments and data analysis; R.G.C.M. carried out experiments, performed RNA-seq experiments and data analysis; E.L.R. performed RNA-seq experiments and analysis; S.B. and J.R.Z. designed and generated pseudotyped lentiviral constructs; E.J.D.G. performed SARS-CoV-2 viral infections, imaging, and analysis; G.S. contributed imaging expertise and facilities; R.E.K. and D.N. provided laboratory support; P.J.L. and S.S. supervised experiments and contributed grant support and facilities; J.J.M. and A.P.D. designed and supervised experiments, performed data analysis, contributed grant support, and facilities. All authors contributed to the writing and/or review of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-021-02453-y.

Correspondence and requests for materials should be addressed to S.S. or A.P.D.

Peer review information: Communications Biology thanks Zeping Zhao and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Amam Akhtar.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
